Drugs / CNTY-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06255028 | Feb 2025 → Aug 2028 expected | diffuse cutaneous systemic sclerosis, idiopathic inflammatory myopathy, lupus nephritis, systemic lupus erythematosus | Century Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05336409 | Jan 2023 → Jul 2025 | aggressive B-cell non-Hodgkin lymphoma, indolent B-cell non-Hodgkin lymphoma | Century Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTY-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05336409 ↗ |
| Modality | Cell therapy | “CNTY-101, a CD19-targeted CAR iNK Cell Product” NCT06255028 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05336409 ↗ |
| Target | CD19 | “CNTY-101, a CD19-targeted CAR iNK Cell Product” NCT06255028 ↗ |